Immunoproteomics - Mass spectrometry-based methods to study the targets of the immune response

被引:61
作者
Purcell, AW [1 ]
Gorman, JJ
机构
[1] Univ Melbourne, Dept Microbiol & Immunol & ImmunolD, Parkville, Vic 3010, Australia
[2] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia
关键词
D O I
10.1074/mcp.R300013-MCP200
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian immune system has evolved to display fragments of protein antigens derived from microbial pathogens to immune effector cells. These fragments are typically peptides liberated from the intact antigens through distinct proteolytic mechanisms that are subsequently transported to the cell surface bound to chaperone-like receptors known as major histocompatibility complex ( MHC) molecules. These complexes are then scrutinized by effector T cells that express clonally distributed T cell receptors with specificity for specific MHC-peptide complexes. In normal uninfected cells, this process of antigen processing and presentation occurs continuously, with the resultant array of self- antigen- derived peptides displayed on the surface of these cells. Changes in this peptide landscape of cells act to alert immune effector cells to changes in the intracellular environment that may be associated with infection, malignant transformation, or other abnormal cellular processes, resulting in a cascade of events that result in their elimination. Because peptides play such a crucial role in informing the immune system of infection with viral or microbial pathogens and the transformation of cells in malignancy, the tools of proteomics, in particular mass spectrometry, are ideally suited to study these immune responses at a molecular level. Here we review recent advances in the studies of immune responses that have utilized mass spectrometry and associated technologies, with specific examples from collaboration between our laboratories.
引用
收藏
页码:193 / 208
页数:16
相关论文
共 212 条
[1]  
Adam BL, 2001, PROTEOMICS, V1, P1264, DOI 10.1002/1615-9861(200110)1:10<1264::AID-PROT1264>3.0.CO
[2]  
2-R
[3]   Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides [J].
Admon, A ;
Barnea, E ;
Ziv, T .
MOLECULAR & CELLULAR PROTEOMICS, 2003, 2 (06) :388-398
[4]   Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications [J].
Ahram, M ;
Flaig, MJ ;
Gillespie, JW ;
Duray, PH ;
Linehan, WM ;
Ornstein, DK ;
Niu, SL ;
Zhao, YM ;
Petricoin, EF ;
Emmert-Buck, MR .
PROTEOMICS, 2003, 3 (04) :413-421
[5]   Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules [J].
Andersen, MH ;
Tan, L ;
Sondergaard, I ;
Zeuthen, J ;
Elliott, T ;
Haurum, JS .
TISSUE ANTIGENS, 2000, 55 (06) :519-531
[6]  
Andersen MH, 1999, J IMMUNOL, V163, P3812
[7]  
Appella E, 1995, EXS, V73, P105
[8]   MOLECULAR REQUIREMENTS FOR THE INTERACTION OF CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES AND INVARIANT CHAIN WITH CALNEXIN [J].
ARUNACHALAM, B ;
CRESSWELL, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (06) :2784-2790
[9]   Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis [J].
Ballot, E ;
Bruneel, A ;
Labas, V ;
Johanet, C .
CLINICAL CHEMISTRY, 2003, 49 (04) :634-643
[10]  
Banks RE, 1999, ELECTROPHORESIS, V20, P689, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<689::AID-ELPS689>3.0.CO